

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trad mark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		A	TORNEY DOCKET NO.	
09/308,140	12/30/99	BYASS		L	LEVER-620X(F	
-		·	7		EXAMINER	
000201 UNILEVER		HM22/1001	·	BUI, P		
PATENT DEPARTMENT 45 RIVER ROAD				ART UNIT	PAPER NUMBER	
EDGEWATER	NJ 07020			1638 Date Wailed:	10/01/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/308,140

Applio (s)

Byass et al.

Examiner

Phuong Bui

Art Unit 1638



 The MAILING DATE of this communication appear 	s on the cov r sheet with the correspondence address
Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SE THE MAILING DATE OF THIS COMMUNICATION.	TTO EXPIRE1 MONTH(S) FROM
 Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. 	
- If the period for reply specified above is less than thirty (30) days, a rej	bly within the statutory minimum of thirty (30) days will
 be considered timely. If NO period for reply is specified above, the maximum statutory period communication. 	will apply and will expire SIX (6) MONTHS from the mailing date of this
 Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). 	e, cause the application to become ABANDONED (35 U.S.C. § 133). ng date of this communication, even if timely filed, may reduce any
Status	
1) Tesponsive to communication(s) filed on	
2a) ☐ This action is FINAL . 2b) ☒ This act	ion is non-final.
3) ☐ Since this application is in condition for allowance e closed in accordance with the practice under Ex p	xcept for formal matters, prosecution as to the merits is arte Quay/035 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 🗓 Claim(s) <u>1-20</u>	is/are pending in the applica
4a) Of the above, claim(s)	is/are withdrawn from considera
5)	is/are allowed.
6)	•
7) 🗌 Claim(s)	is/are objected to.
8) 💢 Claims <u>1-20</u> *	are subject to restriction and/or election requirem
Application Papers	
9) ☐ ₄The specification is objected to by the Examiner.	
10) The drawing(s) filed on is/a	are objected to by the Examiner.
11) The proposed drawing correction filed on	is: a☐ approved b)☐disapproved.
12) \square The oath or declaration is objected to by the Examin	er.
Priority under 35 U.S.C. § 119	
13) 🗓 Acknowledgement is made of a claim for foreign prior	ority under 35 U.S.C. § 119(a)-(d).
a)⊠ All b) ☐ Some* c) ☐None of:	
1. \square Certified copies of the priority documents have	been received.
2. Certified copies of the priority documents have	been received in Application No
3. \(\) Copies of the certified copies of the priority doc application from the International Bureau	ı (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of the 14) Acknowledgement is made of a claim for domestic p	
Additional and the state of a diam for domestic p	monty under 33 0.3.C. § 113(e).
Attachment(s)	
15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20)

DETAILED ACTION

Election/Restriction

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1-4, 7, 11-15, and 18-20, drawn to antifreeze polypeptides, first claimed method of making the polypeptide and first claimed method of using the polypeptide, classified in class 530, subclass 326.
- II. Claims 5-6, drawn to isolated nucleic acid molecules, classified in class 536, subclass 23.6.
- III. Claims 8 and 9, drawn to a second method of obtaining antifreeze polypeptides through recombinant techniques, classified in class 435, subclass 69.1.
- IV. Claims 10 and 17, drawn to an antibody, classified in Class 435, subclass 341.
- V. Claims 14 and 20, drawn to a second method of producing a food product by in situ production, classified in class 435, subclass 419.
- VI. Claim 16, drawn to a non-plant microorganism or cell-line, classified in class 435, subclass 419.

Application/Control Number: 09/308140 Page 2

Art Unit: 1638

For each of inventions I-VI above, restriction to one of the following is also required under 35 USC 121 and 372. Therefore, election is required of one of inventions I-VI and one of inventions (A)-(F).

- (A). SEQ ID No: 1.
- (B). SEQ ID No: 2.
- (C). SEQ ID No: 3.
- (D). SEQ ID No: 4.
- (E). SEQ ID No: 5.
- (F). SEQ ID No: 6 or a sequence encoding SEQ ID No: 7.
- 2. The inventions listed as Groups I-VI and (A)-(F) do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- 3. Inventions (A)-(F) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different polypeptides and the polynucleotides encoding them. Therefore, where structural identity is required, such as for hybridization or expression, the different sequences have different effects.
- 4. Inventions I, II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different

functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to divergent molecules having different functions and effects. The polynucleotides can be used in hybridization assays as well as in expression methods for producing the polypeptides. The polypeptides function as antifreeze polypeptides. The antibody can be used for both passive immunization and protein detection.

- Inventions III and V, and I are related as second claimed processes of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the product as claimed can be made by another and materially different process as evidenced by the two different processes for making the polypeptide and the two different processes for making the food product.
- 6. Inventions II and VI are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not rely solely upon the particulars of the subcombination as claimed because the non-plant microorganism or cell line represents a materially different organism from a transgenic plant. The subcombination has separate utility such as for use in a detection method employing DNA hybridization.

Application/Control Number: 09/308140 Page 2

Art Unit: 1638

7. Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the literature and sequence searches required for each of the Groups are not required for another of the Groups, restriction for examination purposes as indicated is proper.

- 8. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).
- 10. Papers relating to this application may be submitted to Technology Sector 1 by facsimile transmission. Papers should be faxed to Crystal Mall 1, Art Unit 1638, using fax number (703) 308-4242. All Technology Sector 1 fax machines are available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong Bui whose telephone number is (703) 305-1996. The Examiner can normally be reached Monday-Friday from 6:30 AM - 4:00 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Paula Hutzell, can be reached at (703) 308-4310.

Art Unit: 1638

Any inquiry of a general nature or relating to the status of this application should be directed to the receptionist whose telephone number is (703) 308-0196.

Phuong Bui Primary Examiner Group Art Unit 1638 September 25, 2001

> PHUONG T. BÚI PRIMARY EXAMINER